NEW YORK, Jan 25 (Reuters) - Amgen Inc. on Thursday disclosed negative findings in studies of its Aranesp anemia drug and Vectibix colon cancer treatment, including a higher risk of death among cancer ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
An Update Committee (“Committee”) reviewed and analyzed data published since 2002 through July 2007. MEDLINE and the Cochrane Collaboration Library databases were searched.
April 23, 2007 — Using actual US practice patterns and dosing, epoetin alfa (Epogen; peg-EPO therapy) effectively maintains hemoglobin (Hb) levels in hemodialysis patients, according to a presentation ...
Amgen Inc.’s anemia treatment Aranesp is safe for use in kidney patients whose disease doesn’t require dialysis, a U.S. panel said Monday. Outside advisers to the Food and Drug Administration said the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback